Preclinical evaluation of anti-CD38 therapy in mature T-cell neoplasms
Blood Adv
.
2023 Jul 25;7(14):3637-3641.
doi: 10.1182/bloodadvances.2023009807.
Authors
Colleen Isabelle
1
,
William T Johnson
2
,
Kathleen McConnell
1
,
Ashley Vogel
3
,
Jonathan E Brammer
4
,
Amy Boles
1
,
Robyn Keller
1
,
Paola Sindaco
1
,
Liam Nisenfeld
3
,
Guldeep Uppal
3
,
Neda Nikbakht
5
,
Bruno Calabretta
6
,
Patrizia Porazzi
7
8
,
Jerald Gong
3
,
Nitin Chakravarti
1
,
Pierluigi Porcu
1
,
Anjali Mishra
1
6
Affiliations
1
Sidney Kimmel Cancer Center, Division of Hematologic Malignancies, Thomas Jefferson University, Philadelphia, PA.
2
Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
3
Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University, Philadelphia, PA.
4
Division of Hematology, Department of Internal Medicine, The James Comprehensive Center, The Ohio State University, Columbus, OH.
5
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA.
6
Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
7
Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
8
Center for Cellular Immunotherapies, Division of Hematology/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
PMID:
36989058
PMCID:
PMC10365939
DOI:
10.1182/bloodadvances.2023009807
No abstract available
MeSH terms
ADP-ribosyl Cyclase 1
Humans
Neoplasms*
T-Lymphocytes*
Substances
ADP-ribosyl Cyclase 1
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States